Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Pharma name with multiple recent catalysts: late May and June brought several U.S. approvals and positive late-stage updates including TRUQAP, BAXFENDY, IMFINZI, Datroway, IMFINZI/IMJUDO, and camizestrant SERENA-6 data; shares gained about 9.6% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong profitability ⢠Rising leverage ⢠Weak liquidity AZN's strong profitability and R&D-led growth are offset by weakening liquidity, rising debt, softer quarterly cash conversion, and still-demanding valuation.
Price Behavior
Key Price Behavior Insights: ⢠Above short-term average ⢠Support holding firm ⢠Breakout pending Support Level: $160â162 (stronger: $156.94) Resistance Level: $166â167, then $169.66 AZN is cautiously bullish over the last month, holding above $163.41 with support at $160â162, but needs a break above $169.66 to confirm further upside.
Sentiment & News
Key News Insights: ⢠Regulatory momentum ⢠Pipeline resilience ⢠Split analyst views AstraZeneca faces near-term sentiment pressure from trial setbacks and split analyst views, but positive regulatory progress, a strong pipeline outlook and insider buying support a cautiously constructive outlook.
AI Summary
AZN is now a higher-beta clinical-execution investment: its durable oncology earnings base supports the downside, but upsideâand its premium valuationâdepends on tozorakimab and oncology combinations converting into broad approvals and adoption while cash conversion, leverage, and further late-stage setbacks remain key risks.
Description
AstraZeneca PLC is a global biopharmaceutical company engaged in the discovery, development, manufacture and commercialization of prescription medicines across oncology, cardiovascular, renal and metabolic (CVRM), respiratory, vaccines and rare diseases. Its commercial portfolio and pipeline span established brands and newer therapies for core therapeutic areas, and the company distributes products through primary and specialty care channels across the UK, Europe, the Americas, Asia, Africa and Australasia. Incorporated in 1992 and headquartered in Cambridge, UK, AstraZeneca maintains external R&D collaborations with partners such as Neurimmune AG, BenevolentAI, Lunit and Absci Corporation.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 2 | Jul 9 | AZN | AstraZeneca PLC | Pharma name with multiple recent catalysts: late May and June brought several U.S. approvals and positive late-stage updates including TRUQAP, BAXFENDY, IMFINZI, Datroway, IMFINZI/IMJUDO, and camizestrant SERENA-6 data; shares gained about 9.6% over 21 trading days. | Closed | -8.5% |
| Feb 20 | Feb 27 | AZN | AstraZeneca PLC | Recent high-impact drug catalysts (ENHERTU new 1L breast cancer approval, Baxdrostat NDA Priority Review) plus reiterated 2026 growth guidance and a ~19% 21-day price run with shares ~9% above the 21-day SMA and breaking out of the 188â195 range support near-term continuation for a disciplined momentum trade. | Closed | +2.1% |